Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098576 · ClinicalTrials.gov registry record
Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute
A clinical trial, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- 52
- Enrollment target
NCT03098576 is a clinical trial that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 52 participants.
The verdict
NCT03098576 has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the usefulness of matching patients to targeted therapy by analyzing a tumor sample taken at diagnosis and testing it against 50 cancer-associated genes. Targeted therapy is a highly personalized, newer approach to cancer treatment that aims to more precisely identify and attack cancer cells, in an effort to do less damage to normal cells.
Interventions
- OTHER Matched targeted drug treatment
- OTHER Unmatched standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-03-28 |
| Est. Completion | 2024-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03098576
The ClinicalTrials.gov registry entry for NCT03098576 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matched targeted drug treatment is the first listed.
NCT03098576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03098576 about?
NCT03098576 is a clinical study titled "Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute". The purpose of this study is to examine the usefulness of matching patients to targeted therapy by analyzing a tumor sample taken at diagnosis and testing it against 50 cancer-associated genes. Targeted therapy is a highly personalized, newer approach to cancer treatment that aims to more precisely ...
What is the current status of trial NCT03098576?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2017-03-28. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT03098576?
The interventions under investigation include: Matched targeted drug treatment (OTHER), Unmatched standard of care (OTHER).
Who is sponsoring clinical trial NCT03098576?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.